Ignacio Melero Bermejo-rekin lankidetzan egindako argitalpenak (9)

2021

  1. Advances in immunotherapy for hepatocellular carcinoma

    Nature Reviews Gastroenterology and Hepatology, Vol. 18, Núm. 8, pp. 525-543

2013

  1. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C

    Journal of Hepatology, Vol. 59, Núm. 1, pp. 81-88

2011

  1. International symposium on CTL and immunostimulation, Pamplona (Spain), October 26th and 27th 2010

    Cancer Immunology, Immunotherapy

2007

  1. The combined actions of NK and T lymphocytes are necessary to reject an EGFP+ mesenchymal tumor through mechanisms dependent on NKG2D and IFNγ

    International Journal of Cancer, Vol. 121, Núm. 6, pp. 1282-1295

2005

  1. Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus

    Vaccine, Vol. 23, Núm. 27, pp. 3493-3499

2004

  1. MAGE antigens: Therapeutic targets in hepatocellular carcinoma?

    Journal of Hepatology

2003

  1. CD4+/CD25+ Regulatory Cells Inhibit Activation of Tumor-Primed CD4+ T Cells with IFN-γ-Dependent Antiangiogenic Activity, as well as Long-Lasting Tumor Immunity Elicited by Peptide Vaccination

    Journal of Immunology, Vol. 171, Núm. 11, pp. 5931-5939

  2. Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses

    Journal of Virology, Vol. 77, Núm. 20, pp. 10862-10871

2001

  1. Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunity

    European Journal of Immunology, Vol. 31, Núm. 6, pp. 1780-1789